Is There a Cure for NDI? A New Drug May Give Families Hope

A Partnership That Could Change Everything for NDI Families

For families living with X-linked NDI, the daily reality is relentless. Producing up to 20 liters of urine a day, managing constant thirst, planning every outing around water access — and doing all of it with no real treatment in sight. Just management. Just coping.

That may be beginning to change.

A Seattle-based pharmaceutical company called NephroDI Therapeutics announced today that it has entered a formal development agreement with MSRD, part of the global Otsuka family of pharmaceutical companies, to advance a potential first-ever treatment for X-linked congenital NDI.

The drug is called NDI-5001. It works by activating a pathway in the kidney called AMPK, which can trigger water reabsorption through a completely different route than the one that is broken in X-linked NDI. In animal studies, it showed real promise. The goal of this new partnership is to move it into human clinical studies.

"X-linked NDI pediatric patients and their caregivers currently navigate a lifetime of intense symptom management. There are minimally effective treatments currently available for NDI that do little to significantly improve quality of life for patients and their families." — Rachael Hagan, CEO, NephroDI Therapeutics

This is early-stage news, not an NDI cure announcement. NDI-5001 has not yet been tested in humans, and there is meaningful work ahead before it could reach patients. But this partnership — bringing together NDI specialists, kidney researchers, and the resources of a major pharmaceutical group — is the most concrete step toward a real treatment that the NDI community has seen.

We will be watching this closely and will update our community as the research progresses.

Subscribe to our newsletter to stay informed as this story develops.

subscribe